Vir Biotechnology Inc

NASDAQ:VIRUnited States

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

Contact Information

Headquarters

1800 OWENS STREET, SUITE 900SAN FRANCISCO, CA, United States 94158

Phone

415-906-4324

Fax

302-636-5454

Executives

Independent Chairman of the Board

Vicki Sato

Chief Executive Officer, Director

Marianne De Backer

Chief Financial Officer, Executive Vice President

Jason O'byrne

Executive Vice President, Chief Technology Officer

Ann Hanly

Executive Vice President, Chief Scientific Officer

Jennifer Towne